Title : Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).

Pub. Date : 2021 Mar 15

PMID : 33376097






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Further study of BCL-2/BCL-xL inhibition to enhance osimertinib activity is warranted. osimertinib BCL2 apoptosis regulator Homo sapiens